Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences ledipasvir / Sofosbuvir (Harvoni & authorized generic — legacy breakout) ($M) ($M)
Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary
Latest, Q4 2023
16
Period ended Dec 31, 2023
Change on a year earlier
-50.0%
32 in Q4 2022
History
28 quarters
Since Q1 2017
Sources
20
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Ledipasvir / Sofosbuvir (Harvoni & authorized generic — legacy breakout) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2023 | Dec 31, 2023 | 16 | -50.0% | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2023 | Sep 30, 2023 | 23 | -8.0% | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2023 | Jun 30, 2023 | 15 | -34.8% | Form 10-Q (filed 2023-08-04) ↗ |
| Q1 2023 | Mar 31, 2023 | 15 | -57.1% | Form 10-Q (filed 2023-05-03) ↗ |
| Q4 2022 | Dec 31, 2022 | 32 | -34.7% | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2022 | Sep 30, 2022 | 25 | -44.4% | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2022 | Jun 30, 2022 | 23 | -62.9% | Form 10-Q (filed 2023-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 35 | -37.5% | Form 10-Q (filed 2023-05-03) ↗ |
| Q4 2021 | Dec 31, 2021 | 49 | +444.4% | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2021 | Sep 30, 2021 | 45 | -46.4% | Form 10-Q (filed 2022-11-02) ↗ |
| Q2 2021 | Jun 30, 2021 | 62 | -7.5% | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2021 | Mar 31, 2021 | 56 | -50.0% | Form 10-Q (filed 2022-05-04) ↗ |
| Q4 2020 | Dec 31, 2020 | 9 | -91.1% | Form 10-K (filed 2023-02-22) ↗ |
| Q3 2020 | Sep 30, 2020 | 84 | -32.3% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2020 | Jun 30, 2020 | 67 | -65.3% | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 112 | -50.2% | Form 10-Q (filed 2020-05-06) ↗ |
| Q4 2019 | Dec 31, 2019 | 101 | -56.5% | Form 10-K (filed 2022-02-23) ↗ |
| Q3 2019 | Sep 30, 2019 | 124 | -60.1% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 193 | -41.7% | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2019 | Mar 31, 2019 | 225 | -35.3% | Form 10-Q (filed 2020-05-06) ↗ |
| Q4 2018 | Dec 31, 2018 | 232 | -64.0% | Form 10-K (filed 2021-02-25) ↗ |
| Q3 2018 | Sep 30, 2018 | 311 | -68.0% | Form 10-Q (filed 2019-11-05) ↗ |
| Q2 2018 | Jun 30, 2018 | 331 | -76.0% | Form 10-Q (filed 2019-08-06) ↗ |
| Q1 2018 | Mar 31, 2018 | 348 | -74.6% | Form 10-Q (filed 2019-05-08) ↗ |
| Q4 2017 | Dec 31, 2017 | 644 | – | Form 10-K (filed 2019-02-26) ↗ |
| Q3 2017 | Sep 30, 2017 | 973 | – | Form 10-Q (filed 2018-11-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 1,382 | – | Form 10-Q (filed 2018-08-06) ↗ |
| Q1 2017 | Mar 31, 2017 | 1,371 | – | Form 10-Q (filed 2018-05-09) ↗ |
Breakdown
What makes up ledipasvir / sofosbuvir (harvoni & authorized generic — legacy breakout) ($m)
- Ledipasvir / Sofosbuvir (Harvoni & authorized generic — legacy breakout) — U.S. sales ($M)10 · Q4 2023
- Ledipasvir / Sofosbuvir (Harvoni & authorized generic — legacy breakout) — Europe sales ($M)1 · Q4 2023
- Ledipasvir / Sofosbuvir (Harvoni & authorized generic — legacy breakout) — Rest of World sales ($M)5 · Q4 2023
Cite this data
StockData. (2026). Gilead Sciences Ledipasvir / Sofosbuvir (Harvoni & authorized generic — legacy breakout) ($M) ($M), quarterly Q1 2017–Q4 2023 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/liver_harvoni
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.